Update from the 2013 international neurofibromatosis conference

American Journal of Medical Genetics, Part A

Volumn 164, Issue 12, 2014, Pages 2969-2978

  Plotkin, Scott R ^a   Albers, Anne C ^b   Babovic Vuksanovic, Dusica ^c   Blakeley, Jaishri O ^d   Breakefield, Xandra O ^e   Dunn, Courtney M ^b   Evans, D Gareth ^f   Fisher, Michael J ^g   Friedman, Jan M ^h   Giovannini, Marco ⁱ   Gutmann, David H ^b   Kalamarides, Michel ^j   Mcclatchey, Andrea I ^e   Messiaen, Ludwine ^k   Morrison, Helen ^l   Parkinson, David B ^m   Stemmer Rachamimov, Anat O ^e   Van Raamsdonk, Catherine D ^h   Riccardi, Vincent M ⁿ   Rosser, Tena ^o   Schindeler, Aaron ^p   Smith, Miriam J ^f   Stevenson, David A ^q   Ullrich, Nicole J ^r   van der Vaart, Thijs ^s   Weiss, Brian ^t   Widemann, Brigitte C ^u   Zhu, Yuan ^v   Bakker, Annette C ^w   Lloyd, Alison C ^x   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ HOUSE RESEARCH INSTITUTE   (United States)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l FRITZ LIPMANN INSTITUTE   (Germany)

^m PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

ⁿ Neurofibromatosis Institute   (United States)

^o UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^p UNIVERSITY OF SYDNEY   (Australia)

^q UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^r BOSTON CHILDREN S HOSPITAL   (United States)

^s ERASMUS MEDICAL CENTER   (Netherlands)

^t CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^u NATIONAL CANCER INSTITUTE   (United States)

^v CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^w Children's Tumor Foundation   (United States)

^x UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Merlin; Neurofibromatosis 1; Neurofibromatosis 2; Neurofibromin; NF1; NF2; Preclinical models; Schwannomatosis; SMARCB1; Tumor suppressor

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYL COENZYME A; B RAF KINASE; BEVACIZUMAB; CERULENIN; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FATTY ACID SYNTHASE; HEAT SHOCK PROTEIN 90 INHIBITOR; IFOSFAMIDE; MERLIN; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NEUROFIBROMIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAPAMYCIN; RAS PROTEIN; SELUMETINIB; SIMVASTATIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ACOUSTIC NEURINOMA; ARTICLE; AUTISM; BRAIN METABOLISM; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COGNITIVE THERAPY; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; FRACTIONAL ANISOTROPY; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HEALTH CARE QUALITY; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; LEARNING DISORDER; LONG TERM POTENTIATION; LOSS OF FUNCTION MUTATION; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MENINGIOMA; MOLECULARLY TARGETED THERAPY; MOUSE MODEL; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROBIOLOGY; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROPATHY; NF1 GENE; NF2 GENE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIA; OPTIC NERVE GLIOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHWANNOMATOSIS; SIGNAL TRANSDUCTION; SMARCB1 GENE; SYMPOSIUM; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MODEL; VISUAL ACUITY; ANIMAL; DISEASE MODEL; NEURILEMOMA; ORGANIZATION; PATHOPHYSIOLOGY; RESEARCH; SKIN TUMOR; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; NEURILEMMOMA; NEUROFIBROMATOSES; RESEARCH; SKIN NEOPLASMS;

EID: 84911191642     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36754     Document Type: Article

References (40)

1. Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J. 2000. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54:71-76.
2. Babovic-Vuksanovic D, Messiaen L, Nagel C, Brems H, Scheithauer B, Denayer E, Mao R, Sciot R, Janowski KM, Schuhmann MU, Claes K, Beert E, Garrity JA, Spinner RJ, Stemmer-Rachamimov A, Gavrilova R, Van CF, Mautner V, Legius E. 2012. Multiple orbital neurofibromas, painful peripheral nerve tumors, distinctive face and marfanoid habitus: A new syndrome. Eur J Hum Genet 20:618-625.
3. Baumer P, Mautner VF, Baumer T, Schuhmann MU, Tatagiba M, Heiland S, Kaestel T, Bendszus M, Pham M. 2013. Accumulation of non-compressive fascicular lesions underlies NF2 polyneuropathy. J Neurol 260:38-46.
4. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van HP, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R. 2013. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285-289.
5. Burkitt Wright EM, Sach E, Sharif S, Quarrell O, Carroll T, Whitehouse RW, Upadhyaya M, Huson SM, Evans DG. 2013. Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis. J Med Genet 50:606-613.
6. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M. 2013. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077-1080.
7. Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ. 2008. Neurofibromin regulation of ERK signaling modulates GABA release and learning 1. Cell 135:549-560.
8. de Blank PM, Berman JI, Liu GT, Roberts TP, Fisher MJ. 2013. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. Neuro Oncol 15:1088-1095.
9. de Souza JF, Araujo CG, de Rezende NA, Rodrigues LO. 2013. Exercise capacity impairment in individuals with neurofibromatosis type 1. Am J Med Genet A 161A:393-395.
10. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. 2005. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought. Otol Neurotol 26:93-97.
11. Evans DG, O'Hara C, Wilding A, Ingham SL, Howard E, Dawson J, Moran A, Scott-Kitching V, Holt F, Huson SM. 2011. Mortality in neurofibromatosis 1: In North West England: An assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet 19:1187-1191.
12. Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6.
13. Garg S, Lehtonen A, Huson SM, Emsley R, Trump D, Evans DG, Green J. 2013. Autism and other psychiatric comorbidity in neurofibromatosis type 1: Evidence from a population-based study. Dev Med Child Neurol 55:139-145.
14. Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M. 2014. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol 16:493-504.
15. Gutmann DH, McLellan MD, Hussain I, Wallis JW, Fulton LL, Fulton RS, Magrini V, Demeter R, Wylie T, Kandoth C, Leonard JR, Guha A, Miller CA, Ding L, Mardis ER. 2013. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res 23:431-439.
16. Harder A, Wesemann M, Hagel C, Schittenhelm J, Fischer S, Tatagiba M, Nagel C, Jeibmann A, Bohring A, Mautner VF, Paulus W. 2012. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am J Surg Pathol 36:702-709.
17. Hornigold RE, Golding JF, Leschziner G, Obholzer R, Gleeson MJ, Thomas N, Walsh D, Saeed S, Ferner RE. 2012. The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2. J Neurol Surg B Skull Base 73:104-111.
18. Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A, Hochman T, Goldberg JD, Vega E, Wisoff JH, Golfinos JG, Merkelson A, Roland JT, Allen JC. 2014. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 16:292-297.
19. Kossler N, Stricker S, Rodelsperger C, Robinson PN, Kim J, Dietrich C, Osswald M, Kuhnisch J, Stevenson DA, Braun T, Mundlos S, Kolanczyk M. 2011. Neurofibromin (Nf1) is required for skeletal muscle development. Hum Mol Genet 20:2697-2709.
20. Krab LC, de Goede-Bolder A, Aarsen FK, Pluijm SM, Bouman MJ, van der Geest JN, Lequin M, Catsman CE, Arts WF, Kushner SA, Silva AJ, de Zeeuw CI, Moll HA, Elgersma Y. 2008. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: A randomized controlled trial. JAMA 300:287-294.
21. Lammert M, Friedman JM, Kluwe L, Mautner VF. 2005. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 141:71-74.
22. Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ. 2005. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15:1961-1967.
23. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG. 2010. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140:477-490.
24. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, Pan D. 2012. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 26:1300-1305.
25. Peyre M, Stemmer-Rachamimov A, Clermont-Taranchon E, Quentin S, El-Taraya N, Walczak C, Volk A, Niwa-Kawakita M, Karboul N, Giovannini M, Kalamarides M. 2013. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. Oncogene 32:4264-4272.
26. Plotkin SR, Merker VL, Muzikansky A, Barker FG, Slattery W III. 2014. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35:e50-e56.
27. Pong WW, Higer SB, Gianino SM, Emnett RJ, Gutmann DH. 2013. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation 2. Ann Neurol 73:303-308.
28. Quinlan KG, Seto JT, Turner N, Vandebrouck A, Floetenmeyer M, Macarthur DG, Raftery JM, Lek M, Yang N, Parton RG, Cooney GJ, North KN. 2010. Alpha-actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered calcium handling in skeletal muscle. Hum Mol Genet 19:1335-1346.
29. Rauen KA. 2013. The RASopathies. Annu Rev Genomics Hum Genet 14:355-369.
30. Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A, Schacke S, Hagel C, Mautner VF, Hanemann CO, Dun XP, Parkinson DB, Weis J, Schroder JM, Gutmann DH, Giovannini M, Morrison H. 2013. Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci 16:426-433.
31. Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO. 2002. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 125:996-1004.
32. Stevenson DA, Allen S, Tidyman WE, Carey JC, Viskochil DH, Stevens A, Hanson H, Sheng X, Thompson BA, Okumura MJ, Reinker K, Johnson B, Rauen KA. 2012. Peripheral muscle weakness in RASopathies. Muscle Nerve 46:394-399.
33. Sullivan K, El-Hoss J, Quinlan KG, Deo N, Garton F, Seto JT, Gdalevitch M, Turner N, Cooney GJ, Kolanczyk M, North KN, Little DG, Schindeler A. 2014. NF1 is a critical regulator of muscle development and metabolism 1. Hum Mol Genet 23:1250-1259.
34. Tanaka K, Eskin A, Chareyre F, Jessen WJ, Manent J, Niwa-Kawakita M, Chen R, White CH, Vitte J, Jaffer ZM, Nelson SF, Rubenstein AE, Giovannini M. 2013. Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res 19:3856-3870.
35. Trivedi R, Byrne J, Huson SM, Donaghy M. 2000. Focal amyotrophy in neurofibromatosis 2. J Neurol Neurosurg Psychiatry 69:257-261.
36. van der Vaart T, Plasschaert E, Rietman AB, Renard M, Oostenbrink R, Vogels A, de Wit MC, Descheemaeker MJ, Vergouwe Y, Catsman-Berrevoets CE, Legius E, Elgersma Y, Moll HA. 2013. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): A randomised, placebo-controlled trial. Lancet Neurol 12:1076-1083.
37. van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, Thibert RL, Cole AJ, Leigh FA, Plotkin SR, Thiele EA. 2013. Understanding relationships between autism, intelligence, and epilepsy: A cross-disorder approach. Dev Med Child Neurol 55:146-153.
38. Violante IR, Ribeiro MJ, Edden RA, Guimaraes P, Bernardino I, Rebola J, Cunha G, Silva E, Castelo-Branco M. 2013. GABA deficit in the visual cortex of patients with neurofibromatosis type 1: Genotype-phenotype correlations and functional impact. Brain 136:918-925.
39. Walsh KS, Velez JI, Kardel PG, Imas DM, Muenke M, Packer RJ, Castellanos FX, Acosta MT. 2013. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 55:131-138.
40. Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ. 2013. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: An NF clinical trials consortium phase II study. Pediatr Blood Cancer 61:982-986.